国产亚洲综合一区二区在线观看_免费看成年AAA级毛片_艳妇臀荡h乳欲伦交换漫画_亚洲中国成人影院_午夜无码福利片国产播放_成人亚洲欧美日韩_狠狠躁天天躁无码中文幕_在线内射色网视频_免费的黄漫18禁动漫网站_无遮挡又黄又爽又刺激视频

SMET12 is a fully human bispecific antibody targeting EGFR on tumor cells and CD3 on T cells. Developed based on CentryMed's proprietary antibody screening library and bispecific antibody platform, it is the world's first intravenous EGFR×CD3 bispecific antibody and the first in China to receive clinical trial approval from the NMPA. SMET12 recruits and activates T cells to release cytokines, directly killing tumor cells with a low risk of cytokine release syndrome (CRS).

DNV3 is a LAG-3 antibody developed from CentryMed's proprietary high-capacity IgM antibody library. Representing one of the most promising immune checkpoint inhibitors beyond PD-1/PD-L1, DNV3 was initially developed for autoimmune diseases. Preclinical and clinical data indicate its strong potential to reverse resistance to PD-1/PD-L1 inhibitors. DNV3 binds to LAG-3 on activated T cells, directly activating the LAG-3 pathway. This initiates LAG-3 signaling, inhibiting T cell activity, eliminating inflammatory responses, and ultimately normalizing inflammation and maintaining immune homeostasis.

CMDE005 is a recombinant human anti-EGFR×CD3 enzyme-controlled bispecific antibody developed using CentryMed's proprietary pro-BiTE platform. This drug candidate offers advantages including high expression yield during production, high stability, and a long half-life. It is intended for treating various EGFR-positive advanced solid tumors. CMDE005 received clinical trial approval from China's NMPA in September 2024 and IND clearance from the US FDA in April 2025. The drug is currently in Phase I clinical trials, with patient enrollment ongoing in the fifth dose cohort, placing its clinical progress among the global leaders for this class of therapeutics.